Dorton Katina 4

What Happened
Katina Dorton, a director of Fulcrum Therapeutics (FULC), received a derivative award on June 30, 2026 covering 32,000 shares (reported as acquired at $0.00). This transaction is an equity award/option grant (not a cash purchase or sale) and did not result in immediate cash proceeds or share sales.

Key Details

• Transaction date: June 30, 2026; Form 4 filed July 2, 2026 (appears timely — within the typical two-business-day reporting window).
• Reported acquisition: 32,000 derivative shares, reported at $0.00.
• Shares owned after transaction: Not disclosed in the summary provided (see the full Form 4 for post-transaction holdings).
• Footnote: The option was granted June 30, 2026 and is scheduled to vest in full on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders after the grant date, subject to continued service.
• No 10b5-1 plan, tax-withholding sale, or late-filing flag noted in the provided data.

Context
This filing documents an equity award (derivative security) to a director — a routine form of compensation for board service. The award grants the right to acquire shares in the future under a vesting schedule; it is not an immediate purchase or sale of stock and does not by itself indicate buying or selling sentiment. For complete terms (exercise/strike price and plan details) and current holdings, consult the full Form 4 filing.